Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated Jun 06, 2025, titled "Announcement: Company s wholly-owned subsidiary viz. CARBOGEN AMCIS AG has entered into a Co-investment agreement with a long-standing Japan based customer to expand its ADC Manufacturing sites situated at Aarau and Neuland in Switzerland".
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dishman Carbogen Amcis's wholly-owned Swiss subsidiary, CARBOGEN AMCIS AG, has signed a co-investment deal worth over CHF 25 million with a long-standing Japanese customer to expand its antibody-drug conjugate (ADC) manufacturing facilities in Aarau and Neuland, Switzerland. The investment will fund new 850-litre reactors, agitated filter dryers, and supporting infrastructure at both sites, with completion targeted for Q1 and Q3 2027 respectively. The project supports production of a drug linker for a commercial ADC and builds on a similar joint funding deal from April 2021 for the Bubendorf site. CARBOGEN AMCIS is a CDMO serving the pharmaceutical and biopharmaceutical industries with operations across Switzerland, France, the UK, the Netherlands, and China.
This is a positive development, signalling strong demand visibility from a key client and locked-in future revenue for the subsidiary's high-margin ADC services. The capex is largely funded by the customer, limiting balance sheet strain for Dishman while boosting long-term manufacturing capacity and earnings potential.